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Abstract 
Oseltamivir  phosphate or TamifluTM 1, oseltamivir 2 and three new oseltamivir derivatives 11-13 were 
synthesized starting from (-)-shikimic acid 3. The title compounds were evaluated for their anti-Herpes simplex 
virus type-1, anti-alzheimer, anti-tyrosinase activity and cytotoxicity. Compound 12 exhibited inhibitory acitivity 
of HSV-1, AChE, tyrosinase and revealed cytotoxicity against small-cell lung cancer (NCI-H187) cells and Vero 
cells (African green monkey kidney). 
Keywords: shikimic acid, epoxide ring opening, influenza, oseltamivir, oseltamivir phosphate, Tamiflu, anti-
Herpes simplex virus type-1, anti-alzheimer, anti-tyrosinase activity and cytotoxicity. 
 
1. Introduction 
Oseltamivir phosphate or TamifluTM 1 is a potent and selective inhibitor of neuraminidase enzyme of 
influenza type A and B virus [1-5]. To the present date many syntheses of oseltamivir phosphate 1 have 
been documented [6-8, 10-16, 21-23]. While working for development for better synthetic route for 
oseltamivir phosphate, we also interested in evaluation of other biological activity of oseltamivir phosphate 
and its derivatives. Due to availability of a simple, rapid, and sensitive screening methods, oseltamivir 
phosphate 1 and its derivatives 2, 11-13 (scheme 1) were evaluated for their anti-Herpes simplex virus 
type-1, anti-alzheimer, anti-tyrosinase activity and cytotoxicity[9]. 
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Scheme 1. Oseltamivir phosphate 1 oseltamivir 2 and oseltamivir derivatives 11-13. 
 
2. Materials and methods 
The following analytical methods were employed unless otherwise indicated. Melting points were 
determined on a Stuart Scientific Melting Point apparatus (Bibby Sterlin Ltd., UK) and are uncorrected. FT-IR 
spectra were recorded on a Perkin-Elmer FT-IR Spectrum RXI spectrometer (Perkin Elmer Instruments LLC., 
USA). Solutions of samples in dichloromethane or ethyl acetate were dropped onto a potassium bromide crystal 
cell. 1H NMR and 13C NMR spectra were obtained on a Varian Mercury NMR spectrometer operated at 400.00 
MHz for 1H and 100.00 MHz for 13C (Varian Company, USA) using samples dissolved in CDCl3 or D2O. Mass 
spectra were recorded on a Waters Micromass Quatto micro API ESCi (Waters, USA).  
 
3. Results and discussions 
The key intermediate 5-azido-4-hydroxy-3-pentyloxy 9, required for synthesis of oseltamivir phosphate 1, 
its derivatives 2 and 11-13, was synthesized from commercially available (-  ) shikimic acid 3 by modification of 
known methods [6-8] as shown in Scheme 2. 
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Reagents: i:SOCl2, EtOH, heated to reflux, 3.0 h, ii: 3-pentanone, TfOH, rt, 3.0 h, iii: MsCl, Et3N, EtOAc, 
rt, 6.0 h, iv: Et3SiH, AlCl3, CH2Cl2, 0 oC, 5.0 h, v: aq.NaHCO3, EtOH-H2O, 60 oC, 3.0 h, vi: NaN3, NH4Cl, 
EtOH, 70-75 oC, 18.0 h. 
Scheme 2. Synthesis of intermediate   azide  9. 
 
Esterification of (-)-shikimic acid 3 with ethanol and thionyl chloride gave ethyl shikimate 4 in quantitative 
yield. Protection of cis-dihydroxyl group with 3-pentanone in the presence of trifluoromethansulfonic acid 
afforded pentylidene ketal 5 in 83% yield. The hydroxyl group in 5 was protected using methanesulfonyl 
chloride and triethylamine to provide the ketal 6 in 89% yield. The resulting ketal was regioselectively reduced 
to give the hydroxyl ether 7 in 75% yield by modification of known method [Et3SiH and TiCl4 in CH2Cl2 at -32 
oC to 0 oC]. Much cheaper and more easily handled AlCl3 was used in place of TiCl4 and the reaction was carreid 
out at 0 oC. The epoxide 8 was obtained in quantitative yield from reaction of 7 with aq. NaHCO3 in EtOH/H2O, 
at 60 oC. Ring opening of the epoxide 8 with NaN3, NH4Cl in EtOH-H2O at 70-75 oC gave the key intermediate 
hydroxyl azide 9 in 55 % yield. 
 
Acetylation of the hydroxyl azide 9 with acetyl chloride in pyridine, followed by Ph3P reduction of the 
acetylated azide provided new oseltamivir derivative 11 in 70 yield after purification by column chromatography. 
The oseltamivir derivative 12 was obtained in 82% yield after purified by column chromatography from Ph3P 
reduction of the azido group of 9. The new diacetylated compound 13 was obtained in 91% yield from 
acetylations of 12 with AcCl and pyridine. To obtain the acethylated azide 14, the azide 9 was reduced with Ph3P 
followed by ring opening of in situ formed aziridine with NaN3-NH4Cl. The resulting amino azide was then 
acetylated with Ac2O and Et3N to furnish the azide 14 in 36 %yield after column chromatography. Reduction of 
azide 14 with Ph3P in CH3CN-H2O followed by acidification with H3PO4 gave oseltamivir phosphate 1 55% 
yield (2 steps). Oseltamivir phosphate 1 was neutralized by shaking with saturated NaHCO3 provide the free 
base of oseltamivir 2 in quantitative yield. (Scheme 3). The structures of oseltamivir and its derivatives were 
confirmed by their spectroscopic and analytical data. 
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Reagents: i: AcCl, pyridine, CH2Cl2, reflux, 3.0 h, ii: Ph3P, CH3CN-H2O, rt, 3.0 h, iii: Ph3P, CH3CN-H2O, rt, 3.0 
h, iv: AcCl, pyridine, CH2Cl2, reflux, 3.0 h, v: a. Ph3P, DMF, rt, 6.0 h, b. NaN3, NH4Cl, DMF, 70-75 oC, 18-20 h, 
c. Ac2O, Et3N, CH2Cl2, rt, 2.0 h, vi: Ph3P, CH3CN-H2O, rt, 3.0 h, vii: H3PO4, EtOH, rt, viii: sat.NaHCO3, CH2Cl2, 
5 min. 
Scheme 3. Conversion of the azide 9 to oseltamivir phosphate 1, oseltamivir 2 and its derivatives 11-13. 
 
 
4. Biological Activity Screening 
4.1 Anti-Herpes simplex virus type 1 (anti-HSV-1) 
Antiviral activity was determined by using the green fluorescent protein (GFP)-based assay [24]. 
Herpes simplex virus type 1 (HSV-1) was maintained in a Vero cell line (kidney fibroblasts of an African 
green monkey), which was cultured in Eagle’s minimum essential medium (MEM) with the addition of 
10% heat inactivated fetal bovine serum (FBS) and antibiotics. Acyclovir was used as the reference 
compound. None of Oseltamivir and its derivatives showed HSV-1inhibition. 
 
4.2 Anti-alzheimer activity 
Oseltamivir and its derivatives were tested for their acetylcholinesterase inhibitory activity. 
Acetylcholinesterase inhibition was determined by modifying the method of Ellman [25] using 
acetylthiocholine as substrate. Galanthamine was used as a reference standard. Every experiment was done 
in triplicate. Among the test compounds, it is interesting to note that compound 12 exhibited potent anti-
alzheimer activity (IC50 value of 91.14±2.36 µM) with 56.99 % when compare to Galantamine 100.98 %).The 
results shown in table 1. 
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Table 1: Acetylcholinesterase Inhibitory Activity of oseltamivir phosphate 1, oseltamivir 2 and its derivatives 11-
13. 
Compounds  Structure Anti-Acetylcholinesterase Activity 
%Inhibition IC50 (µM) 
Galantaminea 
 
 
100.98 1.45±0.04 
1 
  
C O 2 E t
N H 2 .H 3 P O 4
A c H N
O
 
20.59 Inactiveb 
2 
 
 
14.43 Inactiveb 
11 
 
 
8.49 Inactiveb 
12 
 
 
56.99 91.14±2.36 
13 
 
 
11.92 Inactiveb 
a
 Reference Drug; b Inactive at 0.1 mg/mL. 
4.3 Anti-tyrosinase Activity 
Tyrosinase-inhibition activity was determined by the modified dopachrome method using L-DOPA as 
a substrate [26-27]. The IC50 defined as the concentration of inhibitors required to inhibit tyrosinase activity 
by 50%, was determined. Kojic acid was used as a reference standard. Every experiment was done in 
triplicate. Inbitory activity evaluation of oseltamivir phosphate 1, oseltamivir 2 and its derivatives 11-13 
indicated that compound 12 is more potent than compound 11, however the degree of inhibition is not as 
good as the reference compound. The results are illustrated in table 2. 
Table 2: Anti-tyrosinase Activity of oseltamivir phosphate 1, oseltamivir 2 and its derivatives 11-13. 
Compounds Structure Anti-tyrosinase Activity 
% Inhibition IC50 (µM) 
Kojic acida reference drug 84.06  80.30±0.56 
1 
 
0.66  Inactiveb 
 
2 
 
3.29  Inactiveb 
11 
 
58.55 297.25±4.79 
 
12 
 
67.09 145.22±1.35 
13 
 
1.32 Inactiveb 
a
 Reference Drug; b Inactive at 0.1 mg/mL. 
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4.4 Cytotoxicity 
Oseltamivir phosphate 1, oseltamivir  2 and compound 12 were tested for cytotoxicity. The cytotoxicity 
assays against small-cell lung cancer (NCI-H187) cells, were performed using the resazurin microplate assay, 
which was modified for mammalian cell cytotoxicity [28] and the cytotoxicity assays against Vero cells (African 
green monkey kidney), were performed using the green fluorescent protein (GFP)-based assay [24]. Ellipticine 
was included as the reference drugs. Compound 12 showed cytotoxicity (IC50 value of 25.81 and 33.65 µg/mL 
respectively) the results showed in table 3.  
Table 3: Cytotoxicity of oseltamivir phosphate 1, oseltamivir 2 and its derivatives 12. 
a
 African green monkey kidney cells; b Small cell lung cancer cell;  
c
 Inactive at 50 µg/mL;     d Non-cytotoxic at 50 µg/mL; e Reference Drugs. 
5. Conclusion 
Oseltamivir phosphate 1, oseltamivir 2 and three new oseltamivir derivatives 11-13 were synthesized in this 
work, all in high yield. The synthezised compounds were evaluated for potential inhibitors of HSV-1, AChE and 
tyrosinase. The cytotoxicity assays against small-cell lung cancer (NCI-H187) cells and Vero cells (African 
green monkey kidney) of compounds 1, 2 and 12 were also performed. Among the test compounds, the 
derivative 12 shows AChE and tyrosinase inhibition and also cytotoxicity. It could be noted that the 4-hydroxyl 
group on the core structure of oseltamivir is important for the bioactivities. 
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Experimental Section 
Synthesis of ethyl (3R,4S,5R)-3,4,5-trihydroxy-1-cyclohexene-1-carboxylate (ethyl shikimate) 4 
Thionyl chloride (0.42 g, 5.75 mmol) was added dropwise over to the stirring and ice-cooled solution of (-)-
shikimic acid 3 (2.00 g, 11.50 mmol) in ethanol (10 mL) for 15 min. The reaction was refluxed for 3.0 h, then 
cooled to room temperature and concentrated in vacuo to give the brown oil  of ethyl shikimate 4 (3.50 g, 
quantitative yield), Rf on TLC chromatogram = 0.125 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm): 
1.20 (t, J=6.2 Hz, 3H, -CH3), 2.11(m, 1H, -CH2-), 2.75  (m, 1H, -CH2-), 3.61 (t, J=6.3 Hz, 1H, -CH-OH), 3.96 
(br-s, 1H, -CH-OH), 4.10 (m, 2H, -CH2-CH3), 4.35 (br-s, 1H, -CH-OH), 5.48 (br-s, -OH), 6.73 (m, 1H, -CH=C-); 
13C NMR (CDCl3) (δ, ppm): 14.1 (-CH2CH3), 18.1 (-CH2-), 31.9     (-CH-OH), 61.2 (-CH2CH3), 66.1 (-CH-OH), 
66.7 (-CH-OH), 130.6 (-CH=C-), 136.0 (-CH=C-), 166.7 (-C=O); IR (neat, cm-1): 3360 (-OH), 2910 (-C=C-H), 
1701 (C=O), 1380, 1253 (C=C), 1081(C-O). 
 
Synthesis of ethyl (3aR,7R,7aS)-2,2-diethyl-7-hydroxy-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-
carboxylate (ethyl 3,4-O-isopentylidene-5-hydroxy shikimate) 5 
Trifluoromethane sulfonic acid (0.70 mL, 0.74 mmol) was added dropwise with syringe to the stirring and 
ice-cooled solution of (-)-ethyl shikimate 4 (3.00 g, 14.85 mmol) in 3-pentanone (50 mL). After stirring for 3.0 h 
at room temperature, unreacted 3-pentanone was distilled off with hexane as azeotropic 2:1 mixture to give the 
brown oil, which was redissolved in CH2Cl2 (25 mL), washed with water (2x25 mL), saturated NaHCO3 solution 
(25 mL), and dried over anhydrous Na2SO4. The filtered solution was then concentrated in vacuo to provide the 
brown oil 5 (2.24 g, 83 %),  Rf on TLC chromatogram = 0.50 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, 
ppm): 0.88 (t, J=7.0 Hz, 3H, -C(CH2CH3)2), 0.92 (t, J=7.8 Hz, 3H, -C(CH2CH3)2), 1.30 (t, J=7.0 Hz, 3H, -
CH2CH3), 1.74 (m, 4H, -C(CH2CH3)2), 2.24 (dd, J1=8.6 Hz, J2=17.2 Hz, 1H, -CH2-), 2.78 (dd, J1=4.9 Hz, 1H, -
CH2-), 3.91(m, 1H, -CH-OH), 4.11 (t, J=7.0 Hz, 1H, -CH-O-), 4.22 (q, J=14.9, 2H, -CH2CH3), 4.76 (m, 1H, -
CH-O-), 6.93 (m, 1H, -CH=C-); 13C NMR (CDCl3) (δ, ppm):  7.8 (-C(CH2CH3)2, 8.5 (-C(CH2CH3)2, 14.1 (-
CH2CH3), 29.0 (-CH2-), 29.2 (-C(CH2CH3)2, 29.6                    (-C(CH2CH3)2, 61.0 (-CH2CH3), 68.6 (-CH-OH), 
72.2 (-CH-O-), 77.6 (-CH-O-), 113.5 (-C(CH2CH3)2, 130.2 (-CH=C-), 134.1 (-CH=C-), 166.2 (-C=O); IR (neat, 
cm-1): 3468 (-OH), 2976, 2932 (-C=C-H), 1712, 1650 (C=O), 1460, 1246 (C=C), 1067 (C-O). 
 
Synthesis of ethyl (3aR,7R,7aR)-2,2-diethyl-7-methanesulphonyl-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-
carboxylate (ethyl 3,4-O-isopentylidene-5-methanesulphonyl-shikimate) 6 
Methanesulfonylchloride (0.86 mL, 11.11 mmol) was added dropwise to the stirring solution of 5 (2.00 g. 
7.40 mmol) in EtOAc (10 mL). The reaction was stirred for 15 minutes and then added Et3N (2.00 mL, 14.8 
mmol). After stirring at room temperature for 6.0 hours, the solution was filtered and washed with H2O (2x10 
mL), with 1 M NaHCO3 (2x10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to 
give the brown oil 6 (2.30 g, 89% yield), Rf on TLC chromatogram = 0.65 (50% ethyl acetate:hexane). 1H NMR 
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(CDCl3) (δ, ppm): 0.83 (t, J=5.5 Hz, 3H, (-C(CH2CH3)2), 0.85 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 1.24 (t, J=7.0 
Hz, 3H, (-CH2CH3)), 1.62 (m, 4H, (-C(CH2CH3)2), 2.43 (dd, J1=8.6 Hz, J2=17.2 Hz, 1H, -CH2-), 2.91 (dd, J1=4.7 
Hz, J2=17.2, 1H, -CH2-), 3.05(s, 3H, -OMs), 4.16  (q, J=7.0 Hz, 2H, (-CH2CH3)), 4.25 (t, J=7.0, 1H, (-CH-O-)), 
4.75 (m, 2H, (-CH-O-), -CH-OMs), 6.90 (m, 1H, -CH=C-); 13C NMR (CDCl3) (δ, ppm): 7.8 (-C(CH2CH3)2, 8.6 
(-C(CH2CH3)2, 14.2 (-CH2CH3), 27.9 (-CH2-), 28.9 (-C(CH2CH3)2, 29.6  (-C(CH2CH3)2, 38.7 (-O-SO2-O-CH3), 
61.2 (-CH-OH), 72.3 (-CH-O-), 75.0 (-CH-O-), 79.1 (-CH-O-), 114.4 (-C(CH2CH3)2, 129.3 (-CH=C-), 134.0 (-
CH=C-), 165.3 (-C=O). 
 
Synthesis of ethyl (3R,4R,5R)-3-(1-ethyl-propoxy)-4-hydroxy-5-methanesulfonyloxy-1-cyclohexene-1-
carboxylate 7 
Compound 6 (2.00 g, 5.75 mmol) in CH2Cl2 (5 mL) was added to the stirring, ice-cooled mixture of AlCl3 
(0.92 g, 6.90 mmol) in CH2Cl2 (30 mL) followed by an addition of Et3SiH (1.37 mL, 8.62 mmol). The reaction 
was left at 0 oC for 5.0 h and then quenched by pouring into iced water. The organic layer was separated and 
washed with aqueous NaHCO3, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The 
obtained brown oil was purified by silica gel column chromatography, eluting with 10% ethyl acetate–hexane to 
provide the ethyl 4-hydroxy-5-methansulfonyl-3-pentylideneketal-1-cyclohexene-1-carboxylate 7 (1.50 g, 75%), 
Rf on TLC chromatogram = 0.60 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm): 0.86 (t, J=7.0 Hz, 3H, 
(-C(CH2CH3)2), 0.90 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 1.27 (t, J=7.0 Hz, 3H, (-CH2CH3)), 1.52 (m, 4H, (-
C(CH2CH3)2), 2.49 (dd, J1=6.2 Hz, J2=18.3 Hz, 1H, -CH2-), 2.97 (dd, J1=5.5 Hz, J2=17.9 Hz, 1H, -CH2-), 3.08(s, 
3H, -OMs), 3.41(quint, J=5.5 Hz, 1H, (-CH(CH2CH3)2), 3.91(m, 1H, -CH-O-), 4.19 (m, 2H, (-CH2CH3)), 4.94 
(m, 2H, -CH-OMs, -CH-OH), 6.82 (m, 1H, -CH=C-); 13C NMR (CDCl3) (δ, ppm): 9.4 (-C(CH2CH3)2, 9.6 (-
C(CH2CH3)2, 14.2 (-CH2CH3), 26.1 (-C(CH2CH3)2, 26.4 (-C(CH2CH3)2, 29.3 (-CH2-), 38.7 (-O-SO2-O-CH3), 
61.2 (-CH-OH), 68.6 (-CH-OH), 70.0 (-CH-O-), 71.2 (-CH-OMs), 82.1 (-CH(CH2CH3)2, 129.2 (-CH=C-), 135.0 
(-CH=C-), 165.7 (-C=O). 
 
Synthesis of ethyl (3R,4R,5S)-4,5-epoxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 8 
A mixture of the brown oil of ethyl 5-mesyl-4-hydroxy-5-pentylidene ketal compound 7 (1.00 g, 2.86 
mmol), EtOH (20 mL) and 7.5% NaHCO3 solution, was heated at 60 oC for 3.0 hours. The reaction mixture was 
extracted with n-hexane (4x20 mL), washed with water (20 mL), dried over anhydrous sodium sulfate, filtered 
and concentrated in vacuo to light yellow oil. The residue was purified by recrystalization with hexane at 0 oC to 
give the white crystalline solid 8 (0.70 g, 96.4%),  Rf on TLC chromatogram = 0.63 (50% ethyl acetate:hexane). 
1H NMR (CDCl3) (δ, ppm): 0.94 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 0.96 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 1.26 (t, 
J=7.0 Hz, 3H, (-CH2CH3)), 1.57 (m, 4H, (-C(CH2CH3)2)), 2.40 (dd, J1=6.2 Hz, J2=19.5 Hz, 1H, -CH2-), 3.04 (d, 
J=19.5 Hz, 1H, -CH2-), 3.46 (m, 3H, 2-CH-O-, (-CH(CH2CH3)2), 4.17 (m, 2H, (-CH2CH3)), 4.36 (m, 1H, -CH-
O-), 6.69 (m, 1H, (-CH=C-)); 13C NMR (CDCl3) (δ, ppm): 9.6 (2x-C(CH2CH3)2), 14.2 (-CH2CH3), 24.5 (-CH2-), 
26.5 (2x-C(CH2CH3)2, 50.7 (-CH-O-), 53.4 (-CH-O-), 60.8 (-CH2CH3), 71.3 (-CH-O-), 81.6 (-CH(CH2CH3)2, 
126.9 (-CH=C-), 135.5 (-CH=C-), 166.1 (-C=O). 
 
Synthesis of ethyl (3R,4S,5R)-5-azido-4-hydroxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 9 
A solution of epoxide 8 (0.78 g, 3.07 mmol) in EtOH (3 mL) was added dropwise to the mixture of sodium 
azide (0.40 g, 6.14 mmol), ammonium chloride (0.329 g, 6.14 mmol), water (2 mL) and EtOH (10 mL). The 
reaction mixture was heated at 70 0C for 18 hours. The residue was extracted with EtOAc (20 mL), washed with 
sodium bicarbonate (10 mL), water (2x10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in 
vacuo. The resulting brown oil was purified by column chromatography on silica gel, eluting with 10% ethyl 
acetate–hexane to provide the ethyl 5-azido-4-hydroxy-3-pentylidene ketal compound 9 (0.84 g, 92.72 %), Rf on 
TLC chromatogram = 0.75 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm): 0.88 (t, J=7.8 Hz, 3H, (-
C(CH2CH3)2), 0.92 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2)), 1.28 (t, J=7.0 Hz, 3H, (-CH2CH3)), 1.54 (m, 4H, (-
C(CH2CH3)2), 2.24 (dd, J1=7.0 Hz, J2=18.7 Hz, 1H, -CH2-), 2.74 (br-s, 1H, -OH), 2.87 (dd, J1=5.5 Hz, J2=17.9 
Hz, 1H, -CH2-), 3.42 (quint, J=5.5 Hz, 1H, (-CH(CH2CH3)2)), 3.74 (m, 1H, -CH-N3), 3.85 (q, J=7.0, 1H, -CH-
OH), 4.11 (m, 1H, -CH-O-), 4.20 (q, J=7.0 Hz, 2H, (-CH2CH3)), 6.82 (m, 1H, (-CH=C-)); 13C NMR (CDCl3) (δ, 
ppm): 9.6 (2x-C(CH2CH3)2), 14.2 (-CH2CH3), 26.0 (-C(CH2CH3)2), 26.5 (-C(CH2CH3)2), 28.2 (-CH2-), 58.8 (-
CH-N3), 61.0 (-CH2CH3), 70.3 (-CH-OH), 71.0 (-CH-O-), 81.8  (-CH(CH2CH3)2)), 130.3 (-CH=C-), 135.0 (-
CH=C-), 165.9 (-C=O). 
 
Synthesis of ethyl (3R,4S,5R)-5-azido-4-acetyloxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 10 
A mixture of compound 9 (0.20 g, 0.67 mmol), acetyl chloride (2 mL) and pyridine (0.5 mL) was refluxed 
for 3.0 hours. The reaction mixture was extracted into CH2Cl2 (5 mL) and dried the organic layer over anhydrous 
sodium sulfate, filtered and concentrated in vacuo to give the brown oil of 10 (0.25 g, quantitative yield), Rf on 
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TLC chromatogram = 0.71 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm): 0.81 (t, J=7.0 Hz, 3H, (-
C(CH2CH3)2), 0.87 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 1.23 (t, J=7.0 Hz, 3H , (-CH2CH3)), 1.44 (m, 4H, (-
C(CH2CH3)2)), 2.09 (s, 3H, -C(O)CH3), 2.18 (dd, J1=4.4 Hz, J2=20.0 Hz, 1H, -CH2-), 2.82 (dd, J1=5.5 Hz, 
J2=18.7 Hz, 1H, -CH2-), 3.22 (quint, J=6.2 Hz, 1H, (-CH(CH2CH3)2)), 4.00 (q, J=9.3 Hz, 1H, -CH-N3), 4.15 (q, 
J=7.0 Hz, 2H, (-CH2CH3)), 4.20 (m, 1H, CH-O-), 4.84 (dd, J1=4.0 Hz, J2=9.4 Hz, 1H, -CH-OAc), 6.78 (m, 1H, -
CH=C-); 13C NMR (CDCl3) (δ, ppm): 9.1 (-C(CH2CH3)2), 9.8 (-C(CH2CH3)2), 14.2 (-CH2CH3), 21.1 (-(CO)-
CH3), 24.2 (2x-C(CH2CH3)2), 29.6 (-CH2-), 55.6 (-CH-N3), 61.0 (-CH2CH3), 69.3 (-CH-O-), 73.2 (-CH-O(C=O)-
CH3), 83.0 (-CH(CH2CH3)2)), 129.6 (-CH=C-), 135.2 (-CH=C-), 165.6 (-CH-O(C=O)-CH3), 170.5 (-C=O).  
 
Synthesis of ethyl (3R,4S,5R)-5-amino-4-acetyloxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 11 
Compound 10 (0.20 g, 0.588 mmol) in CH3CN (1 mL) was added dropwise over to the stirring and ice–
cooled solution of triphenyl phosphine (0.30 g, 0.882 mmol) in CH3CN-H2O (5:1) (6 mL) and stirred the mixture 
for 15 minutes, and then  at room temperature for 3.0 hours. The reaction mixture was evaporated to CH3CN and 
then added EtOAc (10 mL). The mixture was washed with water and saturated sodium chloride solution, dried 
over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by column 
chromatography through siliga gel using MeOH–EtOAc (1:9) as eluent to give a yellow oil compound 11 (0.14 
g, 70%), Rf on TLC chromatogram = 0.10 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm): 0.87 (t, J=7.0 
Hz, 3H, (-C(CH2CH3)2), 0.94 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 1.28 (t, J=7.0 Hz, 3H, (-CH2CH3)), 1.47-1.60 (m, 
4H, (-C(CH2CH3)2)), 2.02 (s, 3H, -C(O)CH3), 2.06 (d, J=8.58 Hz, 1H, (-CH2-), 3.04 (dd, J1=4.7 Hz, J2=18.0 Hz, 
1H, -CH2-), 3.44 (quint, J=5.5 Hz, 1H, (-CH(CH2CH3)2), 3.63 (m, 1H, -CH-NH2), 4.06 (m, 1H, (-CH-O(C=O)-
CH3)), 4.17-4.24 (m, 3H, (-CH2CH3), -CH-OAc), 5.80 (m, 1H, (-NH-(C=O)-CH3)), 6.88 (m, 1H, -CH=C-); 13C 
NMR (CDCl3) (δ, ppm): 9.1 (-C(CH2CH3)2), 9.8 (-C(CH2CH3)2), 14.2 (-CH2CH3), 21.1 (-(CO)-CH3), 24.2 (2x-
C(CH2CH3)2), 29.6 (-CH2-), 55.6 (-CH-N3), 61.0 (-CH2CH3), 69.3 (-CH-O-), 73.2 (-CH-O(C=O)-CH3), 83.0 (-
CH(CH2CH3)2)), 129.6 (-CH=C-), 135.2 (-CH=C-), 165.6 (-CH-O(C=O)-CH3), 170.5 (-C=O).  
 
Synthesis of ethyl (3R,4S,5R)-5-amino-4-hydroxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 12 
Compound 9 (0.10 g, 0.337mmol) in CH3CN (1 mL) was added dropwise over to the stirring and ice–
cooled solution of triphenyl phosphine (0.11g, 0.404 mmol) in CH3CN-H2O (3:1) (4 mL) and stirred the mixture 
for 15 minutes, and then at room temperature for 3 hours, the reaction mixture was remove CH3CN to give the 
aqueous solution and then EtOAc (5 mL) was added, the mixture was washed with water and saturated sodium 
chloride solution, dried over anhydrous sodium sulfate. Filtered and concentrated in vacuo and the residue was 
purified by column chromatography through siliga gel using MeOH–EtOAc (1:9) as eluent to give a yellow oil 
compound 12 (0.75 g, 82%), Rf on TLC chromatogram = 0.28 (9:1 ethyl acetate:MeOH). 1H NMR (CDCl3) (δ, 
ppm): 0.78 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 0.82 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 1.20 (t, J=7.0 Hz, 3H, (-
CH2CH3)), 1.44 (m, 4H, (-C(CH2CH3)2), 2.37 (m, 1H, (-CH2-)), 3.01 (dd, J1=4.7 Hz, J2=17.9 Hz, 1H,  (-CH2-)), 
3.37 (quint, J=4.5 Hz, 1H, (-CH(CH2CH3)2), 3.46 (m, 1H, (-CH-NH2)), 3.87 (m, 1H, (-CH-OH)), 4.05 (m, 1H, (-
CH-O-)), 4.12 (q, J=7.0 Hz, 2H, (-CH2CH3)), 6.82 (m, 1H, (-CH=C-)); 13C NMR (CDCl3) (δ, ppm): 9.6 (2x-
C(CH2CH3)2), 14.2 (-CH2CH3), 26.0 (2x-C(CH2CH3)2), 26.5 (-CH2-), 48.5 (-CH-NH2), 61.2 (-CH2CH3), 65.0 (-
CH-OH), 66.0 (-CH-OH), 82.0 (-CH(CH2CH3)2)), 131.0 (-CH=C-), 135.0  (-CH=C-), 166.0 (-C=O), MS (EI) 
[M+H]+ = 272.367. 
 
Synthesis of ethyl (3R,4S,5R)-5-acetamido-4-acetyloxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 13 
A mixture of compound 12 (0.05 g, 0.184 mmol), acytyl chloride (2 mL) and pyridine (0.5 mL) was 
refluxed for 3.0 hours. The reaction mixture was extracted into CH2Cl2 (5 mL), and dried the organic layer over 
anhydrous sodium sulfate, filtered and concentrated in vacuo to give the brown oil 13 (0.60 g, 91%), Rf on TLC 
chromatogram = 0.70 (50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm):  0.87 (t, J=7.0 Hz, 3H, (-
C(CH2CH3)2), 0.93 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 1.27 (t, J=7.8 Hz, 3H, (-CH2CH3)), 1.50 (quint, J=7.0 Hz, 
4H, (-C(CH2CH3)2), 1.94 (s, 3H, (-C(O)CH3)), 2.10 (s, 3H, (-C(O)CH3)), 2.10 (m, 1H, (-CH2-)), 3.00 (dd, J1=5.5 
Hz, J2=18.3 Hz, 1H, (-CH2-)), 3.33 (quint, J=5.5 Hz, 1H, (-CH(CH2CH3)2), 4.13 (m, 1H, (-CH-O-)), 4.18(q, 
J=6.2 Hz, 2H, (-CH2CH3)), 4.57 (quint, J=7.0 Hz, 1H, (-CH-NHAc)), 4.95 (dd, J1=3.1 Hz, J2=11.3 Hz, 1H, (-
CH-OAc)), 5.68(d, J=9.4 Hz, 1H, (-NH-(C=O)-CH3)), 6.83 (m, 1H, (-CH=C-)); 13C NMR (CDCl3) (δ, ppm): 9.3 
(-C(CH2CH3)2), 10.0 (-C(CH2CH3)2), 14.2 (-CH2CH3), 21.3 (-O-(CO)-CH3), 23.5 (-NH-(CO)-CH3), 26.5 (2x-
C(CH2CH3)2), 31.4 (-CH2-), 44.9 (-CH-O-), 61.0 (-CH2CH3), 70.0 (-CH-O-(C=O)-CH3), 72.5 (-CH-NH-(C=O)-
CH3), 83.0 (-CH(CH2CH3)2), 130.8 (-CH=C-), 135.0 (-CH=C-), 165.9 (-C=O),  169.8 (-CH-O-(C=O)-CH3), 
171.7 (-CH-NH-(C=O)-CH3), MS (EI) [M+H+Na]+ = 378.50. 
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Synthesis of ethyl (3R,4R,5S)-4-acetamido-5-azido-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 14  
A solution of ethyl-5-azido-4-hydroxy-3-pentylidene ketal compound 9 (1.70 g. 5.70 mol) in DMF (5 mL) 
was added dropwise to the triphenylphosphin (1.70 g. 5.70 mol) in CH3CN (2 mL). The mixture was heated at 
reflux for 6.0 hours, then concentrated in vacuo to dark brown oil and then the solution of crude in DMF ( 2 mL) 
was added dropwise to the mixture of sodium azide (1.70 g. 5.70 mol), ammonium chloride (1.70 g. 5.70 mol) in 
DMF (2 mL), the  reaction mixture was heated at 80 0C for 18.0 hours, acetic anhydride (2 mL) and 
triethylamine (2 mL) in CH2Cl2 (5 mL) were added to the reaction and then refluxed for 3.0 hours. The reaction 
mixture was extracted with CH2Cl2 (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in 
vacuo to give the brown oil, and purified by column chromatography on silica gel, eluting with 10% ethyl 
acetate–hexane to provide the acetamido azide compound 14 (0.691 g, 36%), Rf on TLC chromatogram = 0.70 
(50% ethyl acetate:hexane). 1H NMR (CDCl3) (δ, ppm):  0.92 (t, J=7.3 Hz, 3H, (-C(CH2CH3)2), 0.93 (t, J=7.3 
Hz, 3H, (-C(CH2CH3)2), 1.32 (t, J=7.1 Hz, 3H, (-CH2CH3)), 1.47-1.59 (m, 4H, (-C(CH2CH3)2), 2.06 (s, 3H, (-
C(O)CH3)), 2.10-2.31 (m, 1H, (-CH2-)), 2.88 (dd, J1=5.7 Hz, J2=17.1 Hz, 1H, (-CH2-)), 3.40 (m, 2H, (-
CH(CH2CH3)2, (-CH-O-)), 4.23 (q, J=7.1 Hz, 2H, (-CH2CH3)), 4.27-4.34 (m, 1H, (-CH-N3)), 4.57-4.60 (m, 1H, 
(-CH-NHAc)), 6.01 (d, J=7.4 Hz, 1H, (-NH-(C=O)-CH3)), 6.81 (dd, J1=2.2 Hz, J2=2.3 Hz, 1H, (-CH=C-)). 
 
Synthesis of ethyl (3R,4R,5S)-4-N-acetamido-5-amino-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 
phosphate (oseltamivir phosphate) 1  
A solution of azido compound 14 (0.69 g. 2.04 mmol) in CH3CN (5 mL) was added dropwise to the 
triphenylphosphine (0.532 g, 2.04 mmol) in CH3CN-H2O (3:1) (12 mL) and stirring was continued for 15 
minutes. After the reaction mixture was stirred at the room temperature for 3.0 hours, the reaction mixture was 
evaporated to CH3CN and then added EtOAc (10 mL). The mixture was washed with water and saturated 
sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue 
was purified by column chromatography through siliga gel using MeOH–EtOAc (1:9) as eluent to give a yellow 
oil compound 2 and dissolve in abs.EtOH (10 mL) and added 85% H3PO4 (1 mL). Crystallization commenced 
immediately and after cooling to 0 oC for 12 hours the precipitate was collected by filtration to afford tamiflu 1 
(0.462 g, 55%)  [  ], Rf on TLC chromatogram = 0.15 (9:1 ethyl acetate:MeOH). 1H NMR (CDCl3) (δ, ppm):  
0.65 (t, J=7.0 Hz, 3H, (-C(CH2CH3)2), 0.69 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 1.10 (t, J=7.0 Hz, 3H, (-CH2CH3)), 
1.24-1.43 (m, 4H, (-C(CH2CH3)2), 1.89 (s, 3H, (-NH-C(O)CH3)), 2.32 (m, 1H, (-CH2-)), 2.77 (dd, J1=6.2 Hz, 
J2=16.8 Hz, 1H, (-CH2-)), 3.35 (m, 2H, (-CH(CH2CH3)2), (-CH-NH2.H3PO4)), 3.86 (t, J=10.1 Hz, 1H, (-CH-
NHAc)), 4.06 (q, J=6.2 Hz, 2H, (-CH2CH3)), 4.14 (d, J=9.4 Hz, 1H, (-CH-O-)), 6.83 (m, 1H, (-CH=C-)). 13C 
NMR (CDCl3) (δ, ppm): 8.4 (-C(CH2CH3)2), 8.5 (-C(CH2CH3)2), 13.3 (-CH2CH3), 22.4 (-O-(CO)-CH3), 25.0 (-
C(CH2CH3)2), 25.4        (-C(CH2CH3)2), 28.1 (-CH2-), 49.1 (-CH-NH2.H3PO4), 52.6 (-CH-O-), 62.4 (-CH2CH3), 
75.1 (-CH-NH-(C=O)-CH3), 84.3 (-CH(CH2CH3)2), 127.6 (-CH=C-), 137.9 (-CH=C-), 165.0 (-C=O), 176.0 (-
CH-NH-(C=O)-CH3), MS (EI) M+ = 313.397.  
 
Synthesis of ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate 
(oseltamivir) 2   
Oseltamivir phosphate 1 (0.010 g, 0.238 mmol) dissolved in CH2Cl2 (1 mL) was neutralized by shaking 
with saturated NaHCO3 (3 mL) for 5 min. The organic layer was dried over anhydrous sodium sulfate, filtered 
and concentrated in vacuo to give the free base of oseltamivir 2 in quantitative yield. Rf on TLC chromatogram = 
0.12 (1:4 ethyl acetate:MeOH).  1H NMR (CDCl3) (δ, ppm): 0.88 (t, J=7.8 Hz, 3H, (-C(CH2CH3)2), 0.89 (t, J=7.0 
Hz, 3H, (-C(CH2CH3)2), 1.28 (t, J=7.0 Hz, 3H, (-CH2CH3)), 1.46-1.54 (m, 4H, (-C(CH2CH3)2)), 2.03 (s, 3H, (-
NH-C(O)CH3)), 2.11-2.18 (m, 1H, (-CH2-)), 2.74 (dd, J1=5.5 Hz, J2=17.6 Hz, 1H, (-CH2-)), 3.22 (m, 1H, (-CH-
NH2)), 3.33 (quint, J=5.5 Hz, 1H, (-CH(CH2CH3)2), 3.53 (q, J=9.36 Hz, 1H, (-CH-NHAc)), 4.19 (q, J=7.0 Hz, 
2H, (-CH2CH3)), 5.78 (d, J=7.8 Hz, 1H, (-NH-(C=O)-CH3)), 6.77 (s, 1H, (-CH=C-)), FTIR, cm-1: 3282 (-NH2),  
2954 (C=C-H), 1716 (C=O),  1259, 1095 (C-O), MS (EI) [M+H]+ = 313.397. 
 
Anti-acetylcholinesterase activity 
Materials. Electric-eel AChE (EC 3.1.1.7), acetylthiocholine iodide (ATCI), 5,5′-dithiobis[2-nitrobenzoic acid] 
(DTNB) and galanthamine were purchased from Sigma-Aldrich Co. (St. Louis, MO, U.S.A.). All chemicals and 
solvents used were purchased from E. Merck, Fluka, and Sigma & Aldrich Co., unless stated otherwise. 
Acetylcholinesterase inhibition was determined spectrophotometrically using acetylthiocholine as substrate by 
modifying the method of Ellman[24]. Briefly, in the 96-well plates, 140 µl of 10 mM sodium phosphate buffer 
(pH 8.0), 20 µl of a solution of AChE (0.2 U/mL in 10 mM sodium phosphate buffer, pH 8.0) and 20 µl of test 
compound solution dissolved in 80% methanol (a final concentration of 0.1 mg/mL) were mixed and incubated 
at room temperature for 15 min. The reaction was stated by adding 20 µl of mixture solution of 5 mM DTNB in 
10 mM sodium phosphate buffer (pH 8.0), containing 0.1% bovine serum albumin (BSA) and 5 mM ATCI in 10 
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mM sodium phosphate buffer, pH 8.0 (5:1). The hydrolysis of acetylthiocholine was determined by monitoring 
the formation of the yellow 5-thio-2-nitrobenzoate anion as result of reaction with DTNB and thiocholines, 
catalyzed by enzymes at a wavelength of 405 nm on a Microtiter plate reader (Sunrise, Tecan) and the 
absorbance was measured after 2 minutes of incubation at room temperature. Percentage of inhibition was 
calculated by comparing the rate of enzymatic hydrolysis of ATCI for the sample to that of the blank (80% 
methanol in buffer). Galanthamine was used as a reference standard. Every experiment was done in triplicate. 
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